Salbutamol is a short-acting β₂-adrenergic agonist used to relieve bronchospasm in a range of respiratory conditions. It belongs to the Respiratory Health therapeutic class and is most commonly supplied as a metered-dose inhaler (MDI) delivering 100 µg of salbutamol per puff. In Hong Kong, salbutamol inhalers are generally prescription-only, regulated by the Hong Kong Department of Health. The medication is also marketed under several brand names, including Ventolin®, Salamol®, and Airomir®.
Salbutamol relaxes airway smooth muscle by selectively stimulating β₂-adrenergic receptors located on the bronchial walls. Activation of these receptors triggers a cascade that increases cyclic adenosine monophosphate (cAMP) within smooth-muscle cells, leading to:
Because salbutamol is delivered directly to the lungs via an inhaler, a high proportion reaches the target site while systemic exposure remains low, minimizing unwanted effects.
Salbutamol inhalers are approved in Hong Kong for the relief of symptoms associated with:
These indications are supported by the Hong Kong Department of Health’s product monographs and align with international regulatory approvals.
Current evidence does not support widespread off-label use of salbutamol in Hong Kong. While some studies have explored its role in preventing exercise-induced bronchoconstriction, this indication is already covered under asthma management guidelines, so no separate off-label listing is necessary. No other investigational applications meet the threshold for inclusion.
Absolute Contraindications
Relative Contraindications / Cautions
Special populations such as the elderly may experience heightened systemic effects due to reduced metabolic clearance and should use the lowest effective dose.
These effects usually subside with continued use or by adjusting technique (e.g., breathing out slowly after inhalation).
Patients experiencing any of these should seek urgent care.
Routine follow-up for patients using salbutamol includes:
If the inhaler feels empty or cannot deliver a full spray, replace it promptly-partial doses may not provide adequate bronchodilation.
This article provides educational information about salbutamol and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Yes, salbutamol inhalers are recognized for personal medical use in most countries. Carry the inhaler in its original packaging, include a copy of the prescription (if required), and be prepared to show the medication at security checkpoints. Some airlines restrict large quantities, so limit yourself to the amount needed for the trip.
Most salbutamol MDIs contain propellants such as hydrofluoroalkane (HFA) and may include ethanol as a solvent. Inactive ingredients are generally inert, but patients with known sensitivities to ethanol or specific propellants should verify the exact composition with the manufacturer.
Salbutamol is a short-acting β₂-agonist (SABA) providing rapid relief, whereas formoterol is a long-acting β₂-agonist (LABA) used for maintenance therapy. SABAs treat acute symptoms; LABAs are not intended for rescue use and require concurrent inhaled corticosteroids.
Using a spacer can improve drug deposition in the lungs and reduce oropharyngeal irritation, especially in children or patients with coordination difficulties. Ensure the spacer is compatible with HFA-propelled inhalers.
Yes, concurrent use is common in asthma management. Inhaled corticosteroids address airway inflammation, while salbutamol provides immediate bronchodilation. No direct pharmacokinetic interaction has been identified.
A dry-feeling inhaler may indicate depleted propellant. Verify the dose counter (if present) or test the spray in the air. Do not attempt to refill; obtain a new inhaler as soon as possible to ensure effective dosing.
Smoking can cause airway irritation and chronic inflammation, potentially diminishing the responsiveness to β₂-agonists. Quitting smoking improves overall lung function and the therapeutic benefit of salbutamol.
Salbutamol is not associated with clinically significant changes in body weight. However, high doses may increase metabolic rate slightly, a effect that is generally negligible in routine therapeutic use.
Salbutamol inhaled at therapeutic doses (≤ 200 µg over 12 hours) is permitted under most anti-doping regulations. Athletes should retain a prescription and declare usage when required by sporting authorities.
MDIs use hydrofluoroalkane propellants, which have a modest global warming potential. Proper disposal at pharmacy take-back programs reduces environmental impact compared with discarding in regular trash.
